Several clinical trials (e.g., NCT02983578) are emerging to assess a novel therapeutic agent, AZD9150 (danvatirsen), an antisense oligonucleotide targeting STAT3 in NSCLC subjects. Here, STAT3 is linked to non-small cell lung carcinoma.